Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer
Changhoon Yoo, Boram Han, Hyeong Su Kim, Kyu-pyo Kim, Deokhoon Kim, Jae Ho Jeong, Jae-Lyun Lee, Tae Won Kim, Jung Han Kim, Dae Ro Choi, Hong Il Ha, Jinwon Seo, Heung-Moon Chang, Baek-Yeol Ryoo, Dae Young Zang
Cancer Res Treat. 2018;50(4):1324-1330.   Published online 2018 Jan 8     DOI: https://doi.org/10.4143/crt.2017.526
Citations to this article as recorded by Crossref logo
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study
Jean marc Phelip, Jérôme Desrame, Julien Edeline, Emilie Barbier, Eric Terrebonne, Pierre Michel, Hervé Perrier, Laetitia Dahan, Vincent Bourgeois, Faiza Khemissa Akouz, Emilie Soularue, Valérie Lebrun Ly, Yann Molin, Thierry Lecomte, François Ghiringhell
Journal of Clinical Oncology.2022; 40(3): 262.     CrossRef
Early Recurrence in Resected Gallbladder Carcinoma: Clinical Impact and Its Preoperative Predictive Score
Yuji Shimizu, Ryo Ashida, Teiichi Sugiura, Yukiyasu Okamura, Katsuhisa Ohgi, Mihoko Yamada, Shimpei Otsuka, Takeshi Aramaki, Akifumi Notsu, Katsuhiko Uesaka
Annals of Surgical Oncology.2022; 29(9): 5447.     CrossRef
Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study
Liu-Fang Ye, Chao Ren, Long Bai, Jie-Ying Liang, Ming-Tao Hu, Hui Yang, Zhi-Qiang Wang, Feng-Hua Wang, Rui-Hua Xu, Yu-Hong Li, De-Shen Wang
Investigational New Drugs.2021; 39(3): 836.     CrossRef
Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
Changhoon Yoo, Sang Hyun Shin, Joon-Oh Park, Kyu-Pyo Kim, Jae Ho Jeong, Baek-Yeol Ryoo, Woohyung Lee, Ki-Byung Song, Dae-Wook Hwang, Jin-hong Park, Jae Hoon Lee
Cancers.2021; 13(7): 1647.     CrossRef
Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis
Alexander A. Azizi, Angela Lamarca, Mairéad G. McNamara, Juan W. Valle
Critical Reviews in Oncology/Hematology.2021; 163: 103328.     CrossRef
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
Lu Zou, Xuechuan Li, Xiangsong Wu, Jiujie Cui, Xuya Cui, Xiaoling Song, Tai Ren, Xusheng Han, Yidi Zhu, Huaifeng Li, Wenguang Wu, Xu’an Wang, Wei Gong, Liwei Wang, Maolan Li, Wan Yee Lau, Yingbin Liu
BMC Cancer.2021;[Epub]     CrossRef
A Novel Combination of Bevacizumab with Chemotherapy Improves Therapeutic Effects for Advanced Biliary Tract Cancer: A Retrospective, Observational Study
Sung-Nan Pei, Chun-Kai Liao, Yaw-Sen Chen, Cheng-Hao Tseng, Chao-Ming Hung, Chong-Chi Chiu, Meng-Che Hsieh, Yu-Fen Tsai, Hsiu-Yun Liao, Wei-Ching Liu, Kun-Ming Rau
Cancers.2021; 13(15): 3831.     CrossRef
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Changhoon Yoo, Kyu-pyo Kim, Jae Ho Jeong, Ilhwan Kim, Myoung Joo Kang, Jaekyung Cheon, Byung Woog Kang, Hyewon Ryu, Ji Sung Lee, Kyung Won Kim, Ghassan K Abou-Alfa, Baek-Yeol Ryoo
The Lancet Oncology.2021; 22(11): 1560.     CrossRef
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial
Ali Belkouz, Judith de Vos-Geelen, Ron A. A. Mathôt, Ferry A. L. M. Eskens, Thomas M. van Gulik, Martijn G. H. van Oijen, Cornelis J. A. Punt, Johanna W. Wilmink, Heinz-Josef Klümpen
British Journal of Cancer.2020; 122(5): 634.     CrossRef
miR‐373 inhibits autophagy and further promotes apoptosis of cholangiocarcinoma cells by targeting ULK1
Pin Lv, Yi‐Fan Luo, Wen‐Yi Zhou, Ben Liu, Zheng Zhou, Yong‐Zhong Shi, Ren Huang, Chuang Peng, Zi‐Li He, Jun Wang, Hong‐Hui Zhang, Sheng‐Dan Nie
The Kaohsiung Journal of Medical Sciences.2020; 36(6): 429.     CrossRef
Advances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials
A. Belkouz, J.W. Wilmink, N. Haj Mohammad, J. Hagendoorn, J. de Vos-Geelen, C.H.C. Dejong, M.Y.V. Homs, B. Groot Koerkamp, T.M. van Gulik, M.G.H. van Oijen, C.J.A. Punt, H. Klümpen
Critical Reviews in Oncology/Hematology.2020; 151: 102975.     CrossRef
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer
Ayhan Ulusakarya, Abdoulaye Karaboué, Oriana Ciacio, Gabriella Pittau, Mazen Haydar, Pamela Biondani, Yusuf Gumus, Amale Chebib, Wathek Almohamad, Pasquale F. Innominato
BMC Cancer.2020;[Epub]     CrossRef
Overview of current targeted therapy in gallbladder cancer
Xiaoling Song, Yunping Hu, Yongsheng Li, Rong Shao, Fatao Liu, Yingbin Liu
Signal Transduction and Targeted Therapy.2020;[Epub]     CrossRef
Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study
Keke Nie, Ling Zhang, Yunhong You, Hongmei Li, Xiuhui Guo, Zhongfa Zhang, Chunling Zhang, Youxin Ji
Therapeutic Advances in Medical Oncology.2020; 12: 175883592097084.     CrossRef
The effect of adjuvant chemotherapy in resectable cholangiocarcinoma: A meta-analysis and systematic review
Ming-Liang Wang, Zhang-Yan Ke, Shuai Yin, Chen-Hai Liu, Qiang Huang
Hepatobiliary & Pancreatic Diseases International.2019; 18(2): 110.     CrossRef
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
L. Perkhofer, A. W. Berger, A. K. Beutel, E. Gallmeier, S. Angermeier, L. Fischer von Weikersthal, T. O. Goetze, R. Muche, T. Seufferlein, T. J. Ettrich
BMC Cancer.2019;[Epub]     CrossRef